A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/395 (2006.01) A61K 49/00 (2006.01) A61K 51/10 (2006.01) A61P 37/02 (2006.01) C07K 16/28 (2006.01) C07K 16/46 (2006.01) C12P 21/08 (2006.01)
Patent
CA 2607281
The invention relates to immunotherapeutic compositions and methods for the treatment of autoimmune diseases and disorders in human subjects using therapeutic antibodies that bind to the human CD 19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD 19 antibodies of the IgGl or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti- CD 19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgGl, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD 19 antibodies.
L'invention se rapporte à des compositions et à des méthodes immunothérapeutiques destinées au traitement des maladies et des troubles auto-immuns chez les sujets humains, comprenant l'utilisation d'anticorps thérapeutiques qui se lient à l'antigène CD 19 humain, et qui ont de préférence une activité médiatrice de l'ADCC humaine. L'invention concerne des compostions pharmaceutiques contenant des anticorps anti-CD 19 humains ou humanisés de l'isotype humain IgG1 ou IgG3. L'invention se rapporte également à des compositions pharmaceutiques contenant des anticorps anti-CD 19 humains ou humanisés de l'isotype humain IgG2 ou IgG4, qui sont de préférence des médiateurs de l'ADCC humaine. L'invention porte en outre sur des compositions pharmaceutiques contenant les anticorps anti-CD 19 chimérisés des isotypes IgGl, IgG2, IgG3, ou IgG4, agissant comme médiateurs de l'ADCC humaine. Dans les modes de réalisation préférés, l'invention concerne des compositions pharmaceutiques contenant des anticorps anti-CD 19 monoclonaux humain, humanisés ou chimères.
Gron Hanne
Hamaguchi Yasuhito
Tedder Thomas F.
Yazawa Norihito
Borden Ladner Gervais Llp
Duke University
LandOfFree
Anti-cd19 antibody therapy for autoimmune disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-cd19 antibody therapy for autoimmune disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-cd19 antibody therapy for autoimmune disease will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1914174